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Abstract
Background: Gambian infants were not routinely vaccinated against hepatitis B virus (HBV) before 1986. During
1986–90 the Gambia Hepatitis Intervention Study (GHIS) allocated 125,000 infants, by area, to vaccination or not
and thereafter all infants were offered the vaccine through the nationwide immunisation programme. We report
HBV serology from samples of GHIS vaccinees and unvaccinated controls, and from children born later.
Methods: During 2007–08, 2670 young adults born during the GHIS (1986-90) were recruited from 80 randomly
selected villages and four townships. Only 28% (753/2670) could be definitively linked to their infant HBV
vaccination records (255 fully vaccinated, 23 partially vaccinated [1–2 doses], 475 not vaccinated). All were tested for
current HBV infection (HBV surface antigen [HBsAg]) and, if HBsAg-negative, evidence of past infection (HBV core-
protein antibody [anti-HBc]). HBsAg-positive samples (each with two age- and sex-matched HBsAg-negative samples)
underwent liver function tests. In addition, 4613 children born since nationwide vaccination (in 1990-2007) were tested
for HBsAg. Statistical analyses ignore clustering.
Results: Comparing fully vaccinated vs unvaccinated GHIS participants, current HBV infection was 0.8% (2/255) vs 12.4%
(59/475), p < 0.0001, suggesting 94% (95% CI 77-99%) vaccine efficacy. Among unvaccinated individuals, the prevalence
was higher in males (p = 0.015) and in rural areas (p = 0.009), but adjustment for this did not affect estimated vaccine
efficacy. Comparing fully vaccinated vs unvaccinated participants, anti-HBc was 27.4% (70/255) vs 56.0% (267/475),
p < 0.00001. Chronic active hepatitis was not common: the proportion of HBsAg-positive subjects with abnormal liver
function tests (ALT > 2 ULN) was 4.1%, compared with 0.2% in those HBsAg-negative. The prevalence of antibodies to
hepatitis C virus was low (0.5%, 13/2592). In children born after the end of GHIS, HBsAg prevalence has remained low;
1.4% (15/1103) in those born between 1990–97, and 0.3% (9/35150) in those born between 1998–2007.
Conclusions: Infant HBV vaccination achieves substantial protection against chronic carriage in early adulthood, even
though approximately a quarter of vaccinated young adults have been infected. This protection persists past the potential
onset of sexual activity, reinforcing previous GHIS findings of protection during childhood and suggesting no need for a
booster dose. Nationwide infant HBV vaccination is controlling chronic infection remarkably effectively.
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Background
Chronic infection with hepatitis B virus (HBV) is a
major cause of death from cirrhosis and liver cancer,
chiefly in South-East Asia and sub-Saharan Africa [1,2].
Approximately 60 million people in Africa are chronic-
ally infected with HBV, mostly acquired perinatally or in
early childhood [3,4]. A safe, effective vaccine consisting
of the HBV surface antigen (HBsAg) was introduced in
the 1980s, although coverage was initially limited by cost
[5]. Universal infant vaccination against HBV is now rec-
ommended, and over the past decade three-dose cover-
age of infants has increased greatly across low and
middle income countries. It now exceeds 70% world-
wide, and 90% in The Gambia [6]. Protection by infant
vaccination against infection in early childhood should
suffice to prevent almost all cases of chronic infection in
adults and hence of cirrhosis and liver cancer from
HBV. For, although immunity can wane, HBV infection
that is first acquired after childhood is unlikely to be-
come chronic [1]. However, the expected impact of in-
fant immunisation needs to be monitored.
During 1986–90 the nationwide Gambia Hepatitis Inter-
vention Study (GHIS) allocated 124,577 infants, rando-
mised by area of birth, to HBV vaccination (58,803) or not
[7,8]. Since the end of recruitment into GHIS in February
1990 there has been universal nationwide infant HBV
vaccination as part of the Expanded Programme on Im-
munisation (EPI). Prior to the GHIS, a study of infant
vaccination against HBV in the two Gambian villages of
Keneba & Manduar had begun in 1984, using historical
controls. Both studies and the stepped-wedge design and
sample-size calculation for the GHIS have been described
previously [9-11]. Periodic follow up of vaccinees in both
studies has found evidence of waning anti-HBs antibody
levels and of substantial numbers having had an HBV in-
fection (as indicated by persisting antibody to the HBV
core protein), generally without any persistent clinical
hepatitis. Despite these breakthrough infections, however,
high vaccine efficacy against chronic HBV infection con-
tinued throughout childhood [12-21].
Although several studies have established vaccine effi-
cacy into adolescence, most are in Asia where the pre-
dominant HBV serotypes differ from those in Africa and
some 40% of chronic infection is acquired perinatally from
the mother, whereas in Africa child-to-child transmission
predominates [22-24]. It has not been established whether
protection by infant vaccination continues into adult life,
when repeated sexual exposure is likely.
To assess the long-term efficacy of infant HBV vaccin-
ation, in 2007-08 we tested sera of a number of subjects in
the GHIS cohort (born 1986–90), to compare HBV
markers in fully vaccinated individuals versus unvaccin-
ated concurrent controls. In addition, to assess the
effectiveness of the subsequent Gambian nationwide
immunization program, we surveyed a sample of children
born since 1990, irrespective of their vaccination status.
The serum samples from those born during 1986–90
were tested not only for markers of past and present
HBV infection but also for infection with the hepatitis C
virus (HCV), another major infective cause of cirrhosis
and liver cancer in this population [25]. Among Gambians
born around the middle of the 20th century about 3% be-
came chronically infected with HCV, possibly from non-
sterile injections, and approximately 20% of liver cancers
in later middle age are HCV-related [26-28]. In younger
generations, however, iatrogenic exposures should have
been reduced by sterile precautions, so the prevalence of
chronic HCV infection should be lower.
Methods
This study is based on two cross-sectional surveys in
2007–08. One, described in Figure 1, was of vaccinated
and unvaccinated young adults born during 1986–90
and therefore part of the GHIS, to assess the long-term ef-
ficacy of infant vaccination against current HBV infection
and chronic active hepatitis (CAH, as indicated by alanine
transaminase [ALT] elevation to greater than the upper
limit of normal [ULN: 2 standard deviations above the
population log mean]). We also tested these same individ-
uals for anti-HBV-core-antibody (anti-HBc), which indi-
cates past or current infection with the hepatitis B virus,
and for anti-HCV antibody, which indicates current in-
fection with the hepatitis C virus.
The other survey was of children born since 1990, and
hence potentially covered by the national HBV vaccination
program (which has been included in the nationwide
Gambian Extended Program on Immunisation [EPI] since
1990), to assess the effectiveness of the national program
against current HBV infection.
During 1986–90, The Gambia was divided into 40 areas,
and vaccination began at different times in different areas.
For the present study we selected four of these areas (two
in Central River region, two in Upper River region) non-
randomly, so that two (one from each region) were early
adopters of HBV vaccination, starting in 1987, and two
were late adopters, starting in 1989. In each area we then
randomly selected for the present surveys 20 villages along
with parts of the main town. The present survey of chil-
dren born during 1986–90 took place in all four areas, but
the survey of children born since 1990 was restricted to
the 40 villages in Central River region.
Recruitment took place through mobile clinic days. We
held community consent meetings prior to recruitment at
each site. Participants passed through three desks at the
mobile clinic: one for registration, one for blood collection
and HBsAg field-testing, and one (at which non-study clin-
ical services were also available) for communication of the
test results.
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All local residents aged 1–22 years were invited to par-
ticipate. Written informed consent was obtained from
participants or, where participants were children, a par-
ent or guardian. Local village assistants contacted house-
holds in advance and on the day to identify participants.
If available, census data could be used to help identify
potential participants. We collected a 5ml blood sample
from all born during 1986–90, and hence in the GHIS.
We took only a finger-prick sample for HBsAg field-
testing from those born since 1990, then sought a 5ml
blood sample from those who field-tested HBsAg-
positive, and from the mother of any person (born in
1986–90 or since 1990) found to be HBsAg positive.
Each 5 ml blood sample was placed immediately into a
cool box, and transported to the laboratory at the end of
each day for processing that evening.
Figure 1 describes the survey of those born during
1986–90. Among them, the primary virology measure-
ments were HBsAg (indicating current HBV antigenaemia),
anti-HBc (indicating past or current HBV infection), and
anti-HCV (indicating current hepatitis C infection). HBsAg
was tested in the field by immunochromatography
(Abbot Determine), a highly sensitive and specific test,
and was not re-tested. All other serology was done at
the main MRC laboratory in Fajara, where anti-HBc was
measured by ELISA (DiaSorin, Sallugia). The main anti-
HBc assay was of the long-lived IgG antibody (indicat-
ing past infection), but HBsAg-positive samples were
also tested for the shorter-lived IgM antibody (indicat-
ing recent infection). HBsAg-positive samples were fur-
ther tested for the early antigen (HBeAg), which
indicates high infectivity, or, if this was absent, for anti-
body to it (anti-HBe). Anti-HCV was measured by im-
munoassay (AxSym analyser, Abbott).
To assess chronic active hepatitis (CAH), all HBsAg-
positive samples (with two age-sex-matched HBsAg-
negative samples) underwent liver function tests (ALT
and AST) in Fajara (VITROS DT60-II analyser, Johnson
& Johnson), with ALT > 2xULN used to define it.
Study forms were completed in the field, checked and
transferred to the main MRC unit for double entry.
Demographic information (age, sex, ethnicity and area of
recruitment) was collected to allow linkage to original
vaccination records in the GHIS database. Linkage was
done, blind to vaccination and HBsAg status, by the pro-
gram Reclink2 and by a separately written SQL program;
consolidation of their findings was finalised before
unblinding. Linkage was classed as reliable when all
major information available was consistent with a single
original record.
Figure 1 Flow diagram of the study.
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The study was designed to assess the continued effi-
cacy of infant HBV vaccination. Odds ratios (ORs) and
their 95% confidence intervals (CIs) were used to quan-
tify relationships between vaccination status and ser-
ology. These were calculated by logistic regression,
adjusted for study area, age, sex, and urban or rural lo-
cation. Chi-squared tests were used to assess trends or
heterogeneity. Statistical analyses used STATA 11.0
(StataCorp, Texas).
Role of the funding sources
The sponsors had no role in the design, data collection,
analysis, interpretation, writing or decision to publish
this report. Ethical approval for the study was from the
Gambian Government and The Gambia Government/
MRC Ethics Committee (L2008.05, SCC1084v2).
Results
GHIS Recruits
2670 people born in 1986–90 (and hence possibly in the
GHIS) were recruited, but reliable linkage to the original
GHIS records of vaccination in infancy was possible for only
753 (28%). Recruitment was approximately balanced be-
tween the four study areas: Basse 905 (34%), Mansakonko
633 (24%), Farafenni 572 (21%), and Gambisara 560 (21%).
Of all participants, 1751 (66%) were female and 1681 (63%)
were recruited from villages rather than towns. Regardless
of HBV vaccination history, the prevalence of current hepa-
titis C virus infection among these young adults, as indicated
by anti-HCV antibody, was 0.5% (13/2598).
The prevalence of current hepatitis B infection, as in-
dicated by HBsAg positivity, was 0.8% (2/255) in those
fully vaccinated with 3 or 4 doses in infancy, 12.4% (59/
475) in those unvaccinated, and 17.9% (4/23) among the
few who had been only partially vaccinated (heterogen-
eity p < 0.00001) (Table 1). The crude odds ratio for
HBsAg positivity comparing those fully vaccinated ver-
sus those unvaccinated was 0.06, suggesting 94% vaccine
efficacy (with 95% CI 77-99%). Logistic regression was
used to assess the impact of potential confounders on
the association between vaccination status and HBsAg
positivity, but adjustment for recruitment area, age, sex,
and urban or rural location did not alter the odds ratio.
Comparing fully vaccinated and unvaccinated subjects,
the prevalence of past or present infection (as indicated by
HBsAg positivity or IgG antibody to the HBV core pro-
tein) was 27% (70/255) vs 56% (267/475), p < 0.00001.
Thus, although the prevalence of past or present infection
among young adults is approximately halved by infant vac-
cination, many of the fully vaccinated participants had at
some time been infected.
Among those in either group (vaccinated or not) who
were currently infected (HBsAg-positive), only 8% (5/65)
had IgM antibody to the HBV core protein (indicating that
the onset of infection was only recent). Of these 65 sam-
ples, 17 (26%) also tested positive for the early antigen
(HBeAg-positive, indicating intense infection), 46 (71%)
had antibody to the early antigen, and only 2 (3%) had
neither the early antigen nor antibodies to it detected.
HBsAg positivity was strongly associated with ALT
elevation, indicating some impairment of liver function
(Table 2). Ignoring vaccination status and comparing all
HBsAg-positive samples vs matched HBsAg-negative sam-
ples, the odds ratio for having ALT above the upper limit
of normal (ULN) was 7.1 (26/218 vs 10/472, p < 0.0001),
and the odds ratio for having chronic active hepatitis,
as indicated by ALT > 2xULN, was 34.1 (9/218 vs 1/472).
Although the numbers were small, chronic active hepatitis
was, as expected, even more highly correlated with intense
HBV infection, as indicated by HBeAg positivity.
Participants born since 1990
Among those born since 1990 (since the beginning of
the nationwide vaccination program, which reaches most
but not all of the population) the overall prevalence of
current HBV infection, as indicated by HBsAg positivity,
was only 0.5% (24/4613), about as low as among the
fully vaccinated controls born in 1986–90. When
Table 1 HBsAg status in early adult life by number of
doses of HBV vaccine in infancy among GHIS participants
with reliable original vaccination records still available
HBsAg + (%) 95% CI Odds ratio
HBV vaccine doses
0 59/475 (12.4%) 9.6 - 15.6 1
1 (partially vaccinated) 2/ 13 (15.4%) 1.9 - 45.4 1.28
2 (partially vaccinated) 2/ 10 (20.0%) 2.5 - 55.6 1.76
3 (fully vaccinated) 1/ 63 ( 1.6%) 0.4 - 8.5 0.11
4 (fully vaccinated) 1/192 ( 0.5%) 0.1 - 2.9 0.04
Total 65/753 -
p (trend) <0.0001.
Table 2 ALT elevation by HBsAg status in early adult life,
comparing all HBsAg + cases vs a matched sample of
twice as many HBsAg- controls 1986–90 births tested in
2007–08; analyses ignore vaccination status
HBsAg + cases
(n = 218)
HBsAg- controls
(n = 472)
Odds
ratio*
ALT category*
Below control
mean
76 (34.9%) 288 (61.0%) 1
Mean to ULN 115 (52.8%) 173 (36.7%) 2.5
ALT 1-2x ULN 18 ( 8.3%) 10 ( 2.1%) 6.8
ALT >2x ULN 9 ( 4.1%) 1 ( 0.2%) 34.1
p (trend) <0.0001.
*In HBsAg- controls, mean ALT is 16 IU/L and upper limit of normal (ULN)
is 35 IU/L.
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stratified by 5-year age group there was an increase from
0.2% in those <5 years of age to 1.8% in those >15 years
of age. (Table 3) Those born since 1997 were 1–9 (me-
dian 5) years of age when we surveyed them, and among
them 9/3506 (0.3%) were HBsAg-positive.
There were only five HBsAg-positive children born
since 1990 for whom we could find records showing
they had definitely been vaccinated in infancy against
HBV, and these were accounted for by only two mothers
(three siblings in one family with an HBsAg positive
mother and two in another family with an untested
mother). There were no other associations with HBsAg
positivity apart from the decrease with year of birth.
The consistency of the estimates of the efficacy of full
infant vaccination in the present survey, in previous sur-
veys of GHIS participants and (with historical controls)
in surveys of the Gambian village of Keneba is shown
in Table 4. A review of sero-prevalence rates in
unvaccinated populations shows that the pre-vaccination
HBV prevalence rates in Keneba and in unvaccinated
GHIS controls are reasonably representative of those in
many other parts of West Africa [29,30]: Figure 2. (In one
other Gambian village, Manduar, the pre-vaccination HBV
prevalence rate was somewhat higher.)
Discussion
This study shows that full infant HBV vaccination does
protect strongly against chronic HBV infection (as indi-
cated by detectable circulating levels of the HBV antigen),
but protects less strongly against ever having HBV infec-
tion (as indicated by antibodies to the HBV core protein).
Although in the present survey of people born in 1986–90
the sample of adolescents who had been vaccinated in in-
fancy is relatively small (n = 255), it provides no evidence
that the potential onset of sexual activity has as yet re-
sulted in an increase in chronic HBV infection. Hence, the
high efficacy now seen against chronic HBV infection in
early adult life should result in high efficacy against HBV-
related cirrhosis and liver cancer in future decades, even
without booster doses for teenagers.
The main limitation of our survey was that record
linkage of participants to their original vaccination re-
cords was unexpectedly difficult, and it was not possible
to match the majority of participants born in the late
1980s to the database of original vaccination records.
However, recruitment into our survey was unlikely to
have been materially affected by vaccination status or
HBV serology (both of which would generally have been
unknown). So, there is no good reason to expect that,
given the vaccination status, subclinical differences in
Table 3 HBsAg positivity by age when surveyed in
2007–08 (and hence by year of birth) among 4613 children
born since nationwide vaccination began in 1990 in The
Gambia
Years of age in 2007–08
(and median birth year)
HBsAg positivity/
number tested (%)
1- 5 (2005) 3/1921 (0.2%)
5- 9 (2001) 6/1591 (0.4%)
10-14 (1996) 10/ 825 (1.2%)
15-17 (1993) 5/ 276 (1.8%)
1-17 (2002) 24/4613 (0.5%)
p (trend) <0.0001.
Table 4 Reports from The Gambia of infant HBV vaccination efficacy against chronic HBV infection (HBsAg+) at various
ages in childhood
Number HBsAg+/number tested (%)
Age (years) Vaccinees Controls % vaccine efficacy (and 95% CI)
Nationwide GHIS cohort, born 1986–90 and surveyed periodically in 1990–2008, vs concurrently born controls
~4 4/720 (0.6) 78/816 ( 9.6) 94% (84–98)
~9 4/675 (0.6) 85/823 (10.3) 95% (84–98)
~15 2/492 (0.4) 51/420 (13.2) 97% (92–99)
~20* 2/255 (0.8) 59/475 (12.4) 94% (76–99)
All ages 12/2142 (0.6) 273/2534 (10.8) 95% (mean)
Keneba village, born 1984–2002 and surveyed in 2003, vs historical controls surveyed in 1984
1-4 0/176 (0.0) 24/236 (10.2)
5–9 2/203 (1.0) 32/205 (15.6)
10–14 0/185 (0.0) 19/135 (14.1)
15+ 3/224 (1.3) 8/47 (17.0)
All ages 5/788 (0.6) 83/623 (13.3) 94% mean**
*Present survey in 2007–08; 3 previous GHIS follow-up surveys took place during 1990–2004 [8,14,15]. Results for Keneba were from a survey in 2003 [13] of
vaccinees born 1984–2002 and from a historical survey in 1984 of unvaccinated children.
**Age-specific results are unstable due to small numbers.
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serological status would bias the findings. A minor limi-
tation was that a small number of anti-HBc test results
(13%) were unavailable from the laboratory, so their
values had to be imputed for calculation of the estimate
of vaccine efficacy against ever having been infected.
Partial (one or two dose) vaccination appeared to be
ineffective, but this conclusion is based on only 23 indi-
viduals (of whom four became HBsAg-positive), so it is
not statistically reliable. Previous surveys of the GHIS
cohort suggested substantial vaccine efficacy among
those who received two doses of vaccine, but they too
were based on relatively small numbers [12].
At early 1980s rates of chronic HBV infection, about
10% of unvaccinated five-year-old children would have
been HBsAg-positive. The Gambian nationwide vaccin-
ation programme that began in 1990 may have taken a
few years to achieve good coverage, but since 1997 HBV
three-dose vaccination coverage has been about 90% na-
tionwide. Hence, about 350 of the 3506 children in our
sample of the whole population born since 1997 are
likely to have been unvaccinated in infancy, or only par-
tially vaccinated. If the 1980s infection rates among
unvaccinated children had persisted, about 35 of these
350 would have been expected to be HBsAg-positive,
whereas in fact only nine of these 3506 children were
HBsAg-positive. This low prevalence suggests not only
high efficacy among those vaccinated but also a signifi-
cant degree of herd immunity.
Of the 24 HBsAg-positive children born since 1990,
when nationwide HBV vaccination by the EPI started,
some were probably infected perinatally from the mother.
The evidence for this is two-fold: first, the mothers of
some of these 24 HBsAg-positive children could be
tested, and were more likely to be HBsAg-positive
themselves (5/10) than would be expected from histor-
ical rates of adult prevalence; second, within these 24
children there were two clusters of infected siblings.
Conclusions
Chronic hepatitis B infection
The nationwide vaccination program that began in 1990
has been more effective than might have been predicted
from extrapolation of the GHIS results. The program
offers a birth dose of HBV vaccine plus a three-dose
regimen of HBV-DPT vaccine, and has resulted in a
massive decrease in the prevalence of chronic HBV
1970 1980 1990 2000 2010
0
5
10
15
20
Year of birth
Chronic
HBV infection
(% HBsAg
positive,
& 95% CI)
Figure 2 Prevalence of chronic HBV infection in The Gambia, by year of birth: born before routine infant HBV vaccination; vaccinees
and controls born during the Gambia Hepatitis Intervention Study (GHIS) in 1986–90; born since nationwide infant HBV vaccination.
Key: Number positive for HBV surface antigen (HBsAg)/number surveyed, % positive, and range of ages in years (y) when surveyed. Open
circles = unvaccinated, closed circles = vaccinated in infancy (or supposed to be, in the Gambian EPI). Keneba: Unvaccinated historical controls
(one village, children surveyed in 1984 at ages 1–19 years). West Africa median: Median of survey-specific HBsAg prevalences in 83 population
surveys of unvaccinated children or adults conducted between 1990–2009 in West Africa (Merrill & Hunter, 2011). GHIS: Vaccinees and concurrent
controls in the Gambia Hepatitis Intervention Study of children born in 1986–90, and surveyed for the present study in 2007–08, at ages 17–22
years, 0 · 8% vs 12 · 4% p < 0 · 00001. EPI: Population sample of children born since 1990 and surveyed for the present study in 2007–08 to assess
the effectiveness of nationwide infant HBV vaccination (in the Gambian Expanded Programme on Immunisation), 1990–97 births 1 · 4% vs 1998–2007
births 0 · 3%, p < 0 · 00001.
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infection between those born in the early 1980s and
those born in the present century. Transmission from
mothers may well account for the majority of the few
remaining chronic infections in infants. As most chronic
infection is acquired in early childhood, the significant
downward trend in prevalence by year of birth since
1990 implies increasing effectiveness in the years since
adoption in 1990 of universal HBV vaccination in The
Gambia. This is partly because Gambian EPI coverage
rates are better now than in the early 1990s, and partly
because of herd immunity among children. High levels
of infant vaccination will, however, continue to be
needed, as for many decades there will still be significant
numbers of people chronically infected with HBV in
The Gambia and its neighbours.
Chronic hepatitis C infection
The major decrease in chronic hepatitis B virus infection
because of infant vaccination has been accompanied by
a substantial decrease in chronic hepatitis C virus infec-
tion, probably due to improved sterile precautions in
medical use of needles. Among the controls in a case–
control study of adults in The Gambia there was a sub-
stantial prevalence of HCV (around 5%, 10/190) among
those born before the 1950s but a much lower preva-
lence (0.5%, 1/192) among those born later [28]. In the
present survey of young adults born during 1986–1990
the prevalence of HCV was again only 0.5% (13/2598),
confirming the low HCV prevalence in recent genera-
tions. The present study tested much larger numbers of
Gambians than any previous study and involved a repre-
sentative community sample. Comparison of the results
among older adults in other studies with those among
young adults in the present study suggests a birth cohort
effect involving almost a ten-fold decrease in the preva-
lence of HCV in The Gambia. This suggests that, in The
Gambia as in many other countries, the mid-century
epidemic of iatrogenic HCV infection from unsterilized
needles has been controlled by the sterile procedures of
the last quarter of the century. So, although HBV and
HCV are causes of almost all liver cancer and cirrhosis
deaths today in The Gambia, both should largely vanish
over the coming decades.
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